Covenant Therapeutics is a biotech highly focused on developing novel, first-in-class therapeutics for COPD. In order to efficiently maintain cash flow while minimizing overhead cost, Covenant has extensively obtained external research fundings with minimal overhead cost and have developed current prototype Cov2010, a first-in-class pharmaceutical agent to treat COPD with awarded US patent, thus, undiluted to date.